Table 5

 Demographic, clinical, and biological data on five patients treated with rituximab for diverse autoimmune diseases

CaseDiseaseSex/age/duration (y)Previous ISClinical involvement at beginning of rituximab treatmentNo of infusions × dose (mg)/No of MP pulses/concomitant ISAdverse event (Y/N)Efficacy (Y/N)Time to response (w)/follow up (m)Prednisone initial/lastAuto-Ab initial/lastRelapse (Y/N)/time to relapse (m)
ALC, Allochrysine (sodium aurothiopropanol sulphonate); auto-Ab, autoantibody; AZA, azathioprine; CIC, ciclosporine; CPH, cyclophosphamide; F, female; fluda, fludarabin; HQ, hydroxychloroquine; inflix, infliximab; IS, immunosuppressants; ivIg, intravenous immunoglobulin; m, months; M, male; MP, methylprednisolone; MTX, methotrexate; N, no; NA, not available; neg, negative; pos, positive; SCT, autologous stem cell transplantation; w, weeks; y, years; Y, yes; –, not relevant.
39Anti-synthetase syndromeF/55/19ALC/HQ/ivIg/MTXPolymyositis/pemphigus4×375.m−2NY4/720/18Anti-Jo1: pos/posY/4
40Anti-synthetase syndromeF/53/6MTX/AZA/ivIgPolymyositis4×375.m−2NY4/520/10Anti-Jo1: pos/posN
41SarcoidosisM/37/17NoCervical and mesenteric lymphadenopathy4×375.m−2NY8/1120/10Y/5
42Still’s diseaseF/32/15MTX/inflix/HQ/CICPolysynovitis2×375.m−2/2/MP (1000)/CPHNN–/2100/100
43Systemic sclerosisM/57/6CPH/SCT/fludaSystemic sclerosis5×375.m−2/fludaNN–/5Neg/negAnti-SCL70: pos/pos